Cancer drug cocktail shows promise for tough blood cancers, but study halted early
NCT ID NCT04550442
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a combination of two drugs, venetoclax and azacitidine, in 34 adults with high-risk blood cancers (MDS or CMML) that returned or didn't respond to earlier treatment. The goal was to find the safest dose and see if the combo could shrink or control the cancer. The study was stopped early, but the results may still help doctors understand how to treat these hard-to-manage conditions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT CHRONIC MYELOMONOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Three-Drug cocktail aims to tame transplant complications in blood cancer patients
- New drug combo aims to outsmart resistant leukemia
- Promising combo for IDH1 leukemia hits early snag – trial stopped
- New radiation method may make stem cell transplants safer for older leukemia patients
- Could detoxing metals boost chemo for leukemia?
- New combo attack on stubborn leukemia: chemo then transplant